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Abstract
Objectives-To investigate the prevalence
and characteristics of antibodies to
endothelial cells (aEC) from large vessel
and from microvasculature in a group of
patients with Behcet's disease (BD) to
determine the relationship of these
antibodies with clinical and laboratory
features ofthe disease.
Methods-Thirty patients with BD were
prospectively and consecutively studied.
The aEC were determined by enzyme-
linked immunosorbent assay (ELISA)
using endothelial cells derived from
human umbilical vein (large vessel) as
well as from retroperitoneal adipose tissue
(microvasculature).
Results-Fifteen patients (50%) had aEC,
either directed to large vessel [8(26%)
patients] or microvascular [13(43%)
patients] endothelial cells. The percenitage
of active patients was significantly higher
in the aEC-positive group [12(80%)
patients] compared with the aEC-negative
group [5(33%) patients] (p < 0-05).
Conclusions-Patients with BD have a
high prevalence of aEC when micro-
vascular endothelial cells are used in the
assay. These antibodies seem to be a
marker of disease activity in this con-
dition, previously considered as negative
for autoantibodies.
(Ann Rheum Dis 1994; 53: 265-267)
Antibodies to endothelial cells (aEC) are a
heterogenous group of autoantibodies directed
against antigens located in the cytoplasmic
membrane of endothelial cells. They have been
described in a variety of disorders that have in
common an immune-mediated damage to the
vessel wall.`17 However, most assays for the
detection of aEC use endothelial cells derived
from human umbilical vein (large vessel) as
antigenic source, while vascular damage
involves small vessels in many of these
conditions. As endothelial cells obtained from
different tissues or from vessels of different
sizes have some distinct biological and
antigenic properties,8 a better system to detect
aEC in these cases would be to use endothelial
cells from microvasculature.
Beh9et's disease (BD) is a multisystemic
inflammatory disorder of unknown aetiology.
The underlying pathology is vasculitis
involving both small and large vessels. Previous
studies,9- 11 using human umbilical vein
endothelial cells, have found a relatively low
prevalence of aEC in this disease. However, no
studies have been performed using micro-
vascular endothelial cells.
In this study, we investigated the prevalence
and characteristics of aEC, using endothelial
cells from human umbilical vein as well as from
adipose tissue (microvasculature), in a group of
patients with BD to determine the relationship
of these antibodies with clinical and laboratory
features of the disease.
Patients and methods
PATIENTS
Clinical and laboratory features of 30 patients
with BD [16 female and 14 male, mean (SD)
age 34 (9)], attending the Hospital Clinic of
Barcelona as in- or outpatients, were
prospectively and consecutively studied during
the years 1989-92. All patients fulfilled the
International Study Group for Behget's
Disease criteria for the diagnosis of BD. 12
Major criteria were defined as oral ulcer,
genital ulcer, eye lesions, and skin lesions.
Minor criteria were defined as arthralgia,
arthritis, central nervous system involvement,
gastrointestinal involvement, and arterial and/
or venous thrombosis. Disease was considered
to be clinically active when at least one major
criterion and any number of minor criteria
were present at the time of the study.
HUMAN UMBILICAL VEIN ENDOTHELIAL CELL
CULTURE
Endothelial cells were isolated by collagenase
(Sigma Chemical Co, St Louis, MO) digestion
of human umbilical veins from several ABH
unrelated donors using the method described
by Jaffeet all3 with minor modifications of our
OwIn.5
HUMAN ADIPOSE TISSUE MICROVASCULAR
ENDOTHELIAL CELL CULTURE
Microvascular endothelial cells were obtained
from retroperitoneal adipose tissue from a
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necropsy specimen. Tissue fragments were cut
into 4 mm2 pieces, digested with 0- 1O%
collagenase at 27°C per 30 minutes, washed in
PBS and pressed from the centre towards the
periphery to release endothelial cells. The
obtained mixed population was grown on
gelatin-coated dishes in medium 199 (Gibco)
with d-valine instead of 1-valine to avoid
fibroblast growth. The medium was
supplemented with 20% iron-fortified calf
serum (Hydine, Logan, VT), 200 microgr/ml
endothelial cell growth supplement (Collab-
orative Research, Bedford, MA) and 50 U/ ml
sodium heparin (Fisher Scientific, Fair Town,
NJ). Contaminating fibroblasts were elim-
inated by scraping and, by three weeks, an
homogeneous population of actively growing
endothelial cells (>95% von Willebrand factor
antigen positive) was obtained. Cells were
passed 1:4 every two weeks and used up to
passage 8.
DETERMINATION OF aEC
The aEC were detected by ELISA as
previously described.5 Results were expressed
as binding index (BI) calculated from optical
absorbance (OA) values as follows:
BI =
OA (test sample) -OA (blank) x 100
OA (standard positive)-OA (blank)
A positive sample was defined as a BI greater
than 44% (mean + 3 standard deviations of 50
healthy blood donors). The ELISA was
reproducible with coefficients of variation
within plates of 5% and between plates of
I 1%.
Demographic, clinical and serologicalfeatures of active and inactive patients with Behfet's
disease
Number Sex Age Activiy HUV-aEC RAT-aEC Uveitis CNS Thrombosis
1 F 47 Active
2 M 44 Active +
3 M 45 Active + + + +
4 M 50 Active +
5 M 53 Active + + + +
6 F 28 Active + + + + +
7 F 25 Active + + +
8 F 25 Active
9 F 28 Active + +
10 F 30 Active +
11 F 22 Active + + + +
12 M 35 Active - +
13 M 27 Active - +
14 M 38 Active - + +
15 M 19 Active - + + +
16 M 46 Active - +
17 M 35 Active - + +
18 F 24 Inactive - +
19 M 30 Inactive +
20 F 38 Inactive
21 F 24 Inactive +
22 F 29 Inactive
23 F 38 Inactive
24 F 34 Inactive
25 F 31 Inactive
26 F 48 Inactive
27 M 29 Inactive
28 F 28 Inactive
29 M 32 Inactive
30 M 28 Inactive
HWV-aEC =antibodies to endothelial cells derived from human umbilical vein; RAT-
aEC = antibodies to endothelial cells derived from retroperitoneal adipose tissue; CNS = central
nervous system involvement; Thrombosis = past thrombotic events.
STATISTICAL ANALYSIS
Conventional chi-square analysis and Fisher's
exact test were used for analysing qualitative
differences, Student's t test for comparison of
means in large samples of similar variance, and
the non-parametric Mann-Whitney U test in
small samples.
Results
PREVALENCE OF aEC
Eight of 30 patients with BD (26%) were
found to have a positive titre of aEC when
human umbilical vein endothelial cells were
used in the ELISA. Conversely, 13 patients
(430/o) were positive for aEC when using
endothelial cells derived from human adipose
tissue.
Seven patients negative for aEC derived
from human umbilical vein had aEC from
human adipose tissue. Conversely, only two
patients were positive for aEC from human
umbilical vein and negative for aEC from
microvasculature. In total, 15 patients (50%)
were considered to have aEC, either directed
to large vessel or microvascular endothelial
cells.
RELATIONSHIP BETWEEN aEC AND CLINICAL
AND LABORATORY FEATURES
Demographic, clinical and serological features
of patients with BD are shown in the table. At
the time of the study, 17 patients (57%) had
clinically active disease. Active eye lesions were
present in 11 patients (37%) and central
nervous system involvement in three (10%).
No patient had gastrointestinal involvement or
acute vascular thrombosis at this time.
However, four patients (13%) had a history of
past thrombotic events (deep vein thrombosis
in two cases and superior vena cava thrombosis
in the remaining two cases). Conventional tests
for detection of lupus anticoagulant, as well as
for anticardiolipin, antineutrophil cytoplasmic,
antinuclear, anti-DNA, anti-Ro(SSA), anti-
La(SSB), anti-RNP, and anti-Sm antibodies,
were negative in all patients.
There was no significant difference between
aEC-positive and -negative patients in age and
sex distribution. However, the percentage of
active patients was significantly higher in the
aEC-positive group compared with the aEC-
negative group (p < 0 05). Specifically, 12
(80%) of 15 aEC-positive patients, but five
(33%) of the remaining 15 aEC- negative
patients, had active disease. Furthermore, the
prevalence of active eye lesions and central
nervous system involvement at the time of the
assay were higher in aEC-positive patients
(53% and 20%, respectively) compared with
the prevalence in aEC-negative patients (20%
and 0%), although these differences did not
reach statistical significance. All four patients
with a history of past thrombotic events had
both aEC derived from human umbilical vein
and aEC from human adipose tissue. There
were no differences in the other clinical and
serological features between aEC-positive and
-negative patients.
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Discussion
In this study, we have demonstrated that
patients with BD have a high prevalence of
aEC when microvascular endothelial cells are
used in the assay. Pivetti-Pezzi et al9 have
previously investigated the prevalence of aEC
from human umbilical vein, as well as that of
anticardiolipin antibodies, in a cohort of Italian
patients with BD characterised by a high
degree of genetic homogeneity and by the
presence of retinal vasculitis. While an elevated
prevalence of anticardiolipin antibodies was
found, aEC were identified only in a minority
of patients (23%). In another study, Aydintug
et al'0 disclosed a statistically significant higher
prevalence of aEC in a group of 72 Turkish
patients with BD (18% v 0% in health
controls). These aEC were not cytotoxic for
the endothelial monolayers in vitro, but their
presence correlated with an active disease and
with acute thrombotic events. In contrast,
anticardiolipin antibodies were negative in all
Turkish patients. The discrepancy between
these two reports can be related to the different
disease activity or to the diverse genetic
background of the patients included.
Our finding of a higher prevalence of aEC
when endothelial cells derived from micro-
vasculature were used in the ELISA is of
special relevance. There is considerable struc-
tural and functional heterogeneity between
endothelial cells from different vascular sites.8
Thus cultured endothelial cells from large
vessels and from microvasculature may differ
in surface antigens. As BD vasculitis affects
both small and large vessels, it is conceivable
that some aEC present in this disease can only
be detected when microvascular endothelial
cells are used in the ELISA. Conversely, it is
interesting that we found aEC from human
umbilical vein in all patients with a history of
past thrombotic events involving large vessels
(leg veins and superior vena cava).
The exact pathogenesis of vascular injury in
BD is unclear but it is possible that
immunological injury to endothelial cells may
be important. High levels of von Willebrand
factor antigen have been detected in some
patients with this condition,9 11 14 15 thus
indicating damage to the endothelium.
Whether aEC represent a primary event or they
appear as a result of vascular damage remains
controversial. No evidence for direct
cytotoxicity induced by aEC has been detected
in patients with BD.'° However, other changes
in endothelial cell function rather than cell
killing might be responsible for the patho-
genesis of vascular damage. It is conceivable
that these antibodies may disturb the normal
physiological processes of endothelial cells and
contribute to the development of vasculitis
present in patients with BD. On the other
hand, Aydintug et al70 have proposed that the
endothelial cell surface alterations caused by an
as yet unknown agent in genetically predis-
posed individuals can lead to the formation of
aEC in BD.
Whatever the relationship is between aEC
and vascular damage in BD, these antibodies
- particularly those against microvascular
endothelial cells - seem to be a marker of
disease activity in this condition, previously
considered as negative for autoantibodies.
Similar correlations between aEC and disease
activity have been reported in rheumatoid
vasculitis,2 Wegener's granulomatosis,6 and
lupus nephritis.' However, serial determin-
ations of aEC need to be performed in future
longitudinal studies to confirm the clinical
usefulness of these antibodies in monitoring
disease activity.
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